Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% ...

In addition to Wegovy, incretin mimetics FDA-approved for chronic weight management include Saxenda (liraglutide), also made by Novo Nordisk, and Zepbound (tirzepatide), produced by Fortune 500 ...

An "exciting" new study has found that Semaglutide, the active ingredient of Wegovy and Ozempic, could help people to reduce their alcohol intake. The drugs were originally developed to treat type ...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...

Veru (VERU.O), opens new tab said on Monday its experimental drug in combination with Novo Nordisk's (NOVOb.CO), opens new tab weight-loss treatment Wegovy, helped preserve muscle in older ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Veru Inc. (NASDAQ: VERU), a late clinical stage ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints were total body ...